Delivery Order SPE2DB22D3010-SPE2DB25FP3JC
- Not listed
- The Defense Logistics Agency (DLA) awarded a delivery order valued at $8,026.53 to AmerisourceBergen Drug Corp for the supply of Promacta 50 mg tablets in quantities of 30 units. This non-competitive, firm fixed price delivery order was awarded on August 18, 2025, with an ultimate completion date of September 9, 2025. The pharmaceutical products will be delivered to the place of performance in Conshohocken, Pennsylvania, where AmerisourceBergen maintains its corporate headquarters. This delivery...
- The Defense Logistics Agency (DLA) awarded a delivery order valued at $8,026.53 to AmerisourceBergen Drug Corp for the supply of Promacta 50 mg tablets (30-count units) on August 28, 2025, with completion scheduled for September 19, 2025. The contract employs firm fixed pricing and was awarded on a competitive, non-set-aside basis. AmerisourceBergen, headquartered in Conshohocken, Pennsylvania, will perform this work at its corporate office location. This delivery order represents a child...
- The Defense Logistics Agency awarded a delivery order to AmerisourceBergen Drug Corp on July 21, 2025, for the supply of Promacta 75 mg tablets in quantities of 30 units. This firm fixed-price contract, valued at $24,059.26, represents a non-competitive set-aside award and is scheduled for completion by August 11, 2025. The pharmaceutical product will be delivered to the place of performance in Conshohocken, Pennsylvania, where AmerisourceBergen maintains its corporate headquarters. This...
- The Defense Logistics Agency awarded a delivery order to AmerisourceBergen Drug Corp on August 5, 2025, for the supply of Promacta 50 mg tablets (30-count units) under a firm fixed-price contract with a ceiling value of $16,053.06 and an ultimate completion date of August 26, 2025. This non-set-aside award represents a child contract under AmerisourceBergen's larger Indefinite Delivery Contract (IDC) with DLA Troop Support Medical, a $999.99 billion prime vendor agreement valued through December...
- The Defense Logistics Agency awarded a $12,029.63 delivery order to AmerisourceBergen Drug Corp on July 30, 2025, for the supply of Promacta 75 mg tablets in quantities of 30 units. This competitive, firm fixed-price delivery order, with an ultimate completion date of August 20, 2025, represents a continuation of the company's pharmaceutical supply services to the federal government. The award was executed under AmerisourceBergen's existing Indefinite Delivery Contract with DLA Troop Support...
- The Defense Logistics Agency (DLA) awarded a delivery order valued at $8,026.53 to AmerisourceBergen Drug Corp for the supply of Promacta 50 mg tablets in quantities of 30 units. This firm fixed-price delivery order, issued on August 5, 2025, with an ultimate completion date of August 26, 2025, represents a non-competitive award under the company's existing indefinite delivery contract (IDC) with DLA. The product will be supplied to the place of performance in Conshohocken, Pennsylvania, where...
- The Defense Logistics Agency awarded a delivery order to AmerisourceBergen Drug Corp on July 29, 2025, for the supply of Promacta 50 mg tablets in quantities of 30 units, with a ceiling value of $8,026.53 and a firm fixed price structure. This award represents a non-set-aside competitive procurement that will be performed at the company's facility in Conshohocken, Pennsylvania, with an ultimate completion date of August 19, 2025. The delivery order is issued under AmerisourceBergen Drug Corp's...
- The Defense Logistics Agency awarded a $8,026.53 delivery order to AmerisourceBergen Drug Corp on July 28, 2025, for the supply of Promacta 50 mg tablets in quantities of 30 units. This is a firm fixed-price delivery order with no set-aside designation, competitively awarded under AmerisourceBergen's existing contract vehicle. The product will be delivered to the company's facility in Conshohocken, Pennsylvania, with an ultimate completion date of August 18, 2025. As a major pharmaceutical...
- The Defense Logistics Agency awarded a $4,418.06 firm fixed-price delivery order to AmerisourceBergen Drug Corp on July 28, 2025, for the supply of Promacta 25 mg tablets (30-count units). The contract, which is a child delivery order under a larger indefinite delivery vehicle, carries an ultimate completion date of August 18, 2025, and will be performed at the company's corporate office location in Conshohocken, Pennsylvania. This award was made through open competition with no set-aside...
- The Defense Logistics Agency awarded a delivery order to AmerisourceBergen Drug Corp on July 21, 2025, for the supply of Promacta 75 mg tablets in quantities of 30 units, with a contract ceiling value of $12,029.63 and an ultimate completion date of August 11, 2025. This is a firm fixed-price delivery order issued under a competitive, non-set-aside procurement. AmerisourceBergen Drug Corp, headquartered in Conshohocken, Pennsylvania, will perform this delivery order at its corporate office...
- SPE2DB22D3010Indefinite Delivery Contract
- SPE2DB22D3010-SPE2DB25FP3JCDelivery Order
The Defense Logistics Agency (DLA) awarded a delivery order to AmerisourceBergen Drug Corp on August 29, 2025, for the supply of Promacta 50 mg tablets in quantities of 30 units. This firm fixed price delivery order, valued at $16,053.06, represents a non-set-aside competitive award with an ultimate completion date of September 22, 2025. The pharmaceutical products will be delivered to the place of performance in Conshohocken, Pennsylvania, where AmerisourceBergen maintains its corporate headquarters. This delivery order is issued under AmerisourceBergen's larger Indefinite Delivery Contract (IDC) with DLA Troop Support Medical, designated as SPE2DX and valued at $999,999,999.00 through December 2026. As a prime pharmaceutical vendor for the federal government, AmerisourceBergen supplies a comprehensive range of medications and medical supplies to support military healthcare systems and other federal agencies, including the Defense Health Agency and U.S. Coast Guard. The company's extensive federal procurement portfolio demonstrates its capability to fulfill diverse pharmaceutical requirements across multiple therapeutic domains through competitive federal contracting processes.
Mod # | Description | ReasonForModification | Federal Obligation | Date |
|---|---|---|---|---|
| Not listed | Not listed | $16.1k | 8/29/25 |